AI Lab Promises to Supercharge Drug Discovery 8x ai-beat #AILab #DrugDiscovery #HealthcareInnovation #Biotech #MachineLearning

AI Lab Promises to Supercharge Drug Discovery 8x ai-beat #AILab #DrugDiscovery #HealthcareInnovation #Biotech #MachineLearning
An AI lab that never stops learning just entered drug discovery #ArtificialIntelligence #DrugDiscovery
Interesting talk by Madeeha Ali at #CovModDrugDiscov.
She talked about her exciting work on studying the kinetics of #CovalentInhibitors.
Great talk by David Heppner (@heppnerd.bsky.social) at #CovModDrugDiscov.
He gave exciting insights into rigorously characterizing #CovalentInhibitors using crystal structures and kinetics.
Insightful talk by Matthias Gehringer at #CovModDrugDiscov.
He gave great insights into his group's work on making new kinases amenable to covalent drug discovery at cysteine and beyond.
onlinelibrary.wiley.com/doi/10.1002/...
#CovalentInhibitor #DrugDiscovery #ChemSky #ChemBio #Science #Kinase
We had an amazing poster session at #CovModDrugDiscov! I learned a lot about new warheads, covalent binder optimization and methods to measure target engagement.
Thank you to all presenters for sharing their amazing science.
#DrugDiscovery #ChemSky #ChemBio #Science
@britpharmsoc.bsky.social
Interesting talk by Jonathan Pettinger from GSK at #CovModDrugDiscov.
He talked about the power of direct-to-biology (D2B) approaches for fast SAR studies of #CovalentInhibitors.
#D2B #DirectToBiology #DrugDiscovery #ChemBio #ChemSky #Science
If you are attending BioJapan and would like to learn more about MEDINA or explore potential collaborations, come and meet us at the Spain Pavilion ICEX.
#BioJapan2026 #DrugDiscovery #CellPainting #HighContentScreening #HTS #PhenotypicScreening #NaturalProducts #Biotechnology #FundacionMEDINA
#CovModDrugDiscov continues with an interesting talk by Mandy Ferdinand from Cancer Research Horizons.
She talked about methods to characterize covalent hits with a special focus on binding kinetics.
#CovalentInhibitor #DrugDiscovery #ChemSky #ChemBio #Science
Big Pharma is betting heavily on AI—but will it actually reduce drug development costs?
Explore how AI is transforming drug discovery, clinical trials, pharma R&D and AI ROI.
Read the full analysis: www.sperresearch.com/Blogs/ai-in-...
And we are on the way with the Covalent Modulation in Drug Disvovery Conference by @britpharmsoc.bsky.social.
Looking forward to two days filled with cutting-edge covalent drug discovery.
The global Metagenomic Sequencing Market is projected to grow from USD 3,034.79 million in 2026 to USD 11,026.35 million by 2034, at a 17.5% CAGR.
Get Free Sample:
straitsresearch.com/report/metag...
#Metagenomics #Genomics #Sequencing #Biotechnology #DrugDiscovery #LifeSciences
#EUREMAP EU-OPENSCREEN Facultad de Química - UNAM @Universidad Nacional Autónoma de México European Research Executive Agency (REA)
#MarineNaturalProducts #MarineBioprospecting #NaturalProducts #DrugDiscovery #BlueBioeconomy #HorizonEurope #FundacionMEDINA
A new arXiv preprint introduces MAGI, an open modular agent for drug discovery that combines LLM-generated molecules with REINVENT 4 and was tested across nine retrospective lead-optimization campaigns. LLM proposals…
#AI #OpenSource #DrugDiscovery #LLMAgents
https://arxiv.org/abs/2610.06411
A visionary presenter claims that merging AI with quantum computing could revolutionize drug discovery by grounding medical predictions and minimizing AI hallucinations.
Click to read more!
#MA #CitizenPortal #QuantumInnovation #DrugDiscovery #AITrustworthiness
I am looking forward to an exciting meeting.
#CovalentInhibitor #DrugDiscovery #ChemSky #Chemistry #ChemBio #ChemicalProteomics #ChemPro #ProteoProbes
(3/3)
QSimulate's QUELO platform demonstrates 1,000X speedup over conventional simulations using quantum physics-first calculations. Real customers now complete drug discovery workflows in hours instead of months, with minimal compute overhead.
QC6352, once considered “best-in-class,” has a hidden liability. New research shows it is a dual KDM4–DHODH inhibitor, with DHODH driving activity in glioblastoma models. We’re updating the Chemical Probes Portal with a warning and guidance on controls. #DrugDiscovery
www.nature.com/articles/s41...
Metabolic disease rarely affects only one organ. So how do you capture a therapy's effects beyond its target organ in trial design?
Thursday 15 October, #ELRIGDD26: Anna Veprik presents how multi-organ MR imaging can be used as a precision biomarker in drug discovery.
Want to know more? Swipe through how it works 👇
#NaturalProducts #Biosynthesis #BiosyntheticGeneClusters #DrugDiscovery #GenomeMining #FundacionMEDINA